Showing 5801-5810 of 8543 results for "".
- FDA Clears Illuminate PRP System for Clinical Usehttps://practicaldermatology.com/news/fda-clears-illuminate-prp-system-clinical-use/2468757/Illuminate PRP’s platelet-rich plasma (PRP) system has received FDA clearance for clinical use, the company announced. The FDA-cleared single-spin PRP system offers a fast, efficient method for preparing high-quality PRP with high platelet capture rates, providing physicians with a reliabl
- GW SMHS Teledermatology Program Receives Renewed Fundinghttps://practicaldermatology.com/news/gw-smhs-teledermatology-program-receives-renewed-funding/2468756/The George Washington University School of Medicine and Health Sciences Department of Dermatology, in collaboration with the Pennsylvania Avenue Baptist Church and the National Psoriasis Foundation (NPF), announced a renewed funding commitment of $350,000 from Johnson & Johnson in support of
- Upadacitinib Effective in Adolescents With AD Through 76 Weekshttps://practicaldermatology.com/news/upadacitinib-effective-adolescents-ad-through-76-weeks/2468724/Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib demonstrated a favorable benefit-risk profile, with sustained efficacy responses through 76 weeks, in a study published in JAMA Dermatology. “Upadacitinib in Adolescents With Moderate to Sev
- J&J Seeks FDA Approval for Pediatric Tremfya Indicationshttps://practicaldermatology.com/news/jj-seeks-fda-approval-pediatric-tremfya-indications/2468706/Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremfya (guselkumab), seeking approval for pediatric indications. Tremfya, the first approved monoclonal antibody IL-23 inhibitor that select
- OLYMPIA 1: Nemolizumab Shows Improvements in Prurigo Nodularis Symptomshttps://practicaldermatology.com/news/olympia-1-nemolizumab-shows-improvements-prurigo-nodularis-symptoms/2468705/Results from a multicenter phase 3 clinical trial indicated that nemolizumab monotherapy significantly reduces pruritus and nodular lesions in adults with moderate to severe prurigo nodularis (PN). Researchers for the OLYMPIA 1 trial evaluated the efficacy and safety of nemolizumab in 286
- Study Links Psoriasis Severity to Increased Heart Disease Riskhttps://practicaldermatology.com/news/study-links-psoriasis-severity-increased-heart-disease-risk/2468660/Psoriasis severity is associated with increased cardiovascular risk, according to new research, with systemic inflammation functioning as a key mediator. Data from two cohorts—the Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative (PACI) and the Stockholm Psoriasis Cohort (SP
- SDPA: Strategic Supplement Strategies for the Derm PAhttps://practicaldermatology.com/news/sdpa-strategic-supplement-strategies-derm-pa/2468638/Sara Wilchowski, DMSc, MPAS, PA-C, presented “Strategic Supplement Strategies for the Derm PA” at SDPA’s 22nd Annual Fall Dermatology Conference in Las Vegas. The lecture explored the role of nutraceuticals and alternative medicines in supporting patients in their overall wellness jour
- FDA Greenlights BIMZELX for Chronic Hidradenitis Suppurativahttps://practicaldermatology.com/news/fda-greenlights-bimzelx-chronic-hidradenitis-suppurativa/2468635/The Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for adults with moderate-to-severe hidradenitis suppurativa (HS), making it the first treatment to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F). According to a press release f
- Acne Insights: Strategies and Solutions at 2024 SDPA Fallhttps://practicaldermatology.com/news/acne-insights-strategies-and-solutions-2024-sdpa-fall/2468634/The SDPA’s 22nd Annual Fall Dermatology Conference was held last week at the Fontainebleau in Las Vegas. Conference Medical Director Hilary Baldwin, MD, joined Shanna Miranti, MPAS, PA-C, in a discussion called “Acne Insights: Expert Strategies and Solutions from the Pros.” The presentatio
- Analyses: Ruxolitinib Cream Reduces AD Symptom Burden in 12 Hourshttps://practicaldermatology.com/news/analyses-ruxolitinib-cream-reduces-ad-symptom-burden-12-hours/2468615/Ruxolitinib cream significantly reduced skin pain and improved patient-reported outcomes (PROs) in individuals with mild-to-moderate atopic dermatitis (AD), with improvements sustained over 52 weeks, according to data from the TRuE-AD1 and TRuE-AD2 studies. Researchers the results publishi